Now I have comprehensive information. Let me compile the full clinical response.
Clinical Assessment: 60-Year-Old Male, CKD on MHD - Abdominal "Khichav" (Stretching/Pulling Sensation) + Insomnia
Interpretation of "Khichav" in This Context
The complaint of khichav (stretching, pulling, creeping-crawling discomfort) in the abdomen/body in an MHD patient, with sleep loss the whole night, is highly characteristic of Restless Legs Syndrome (RLS) / Ekbom Syndrome - a very common complication in hemodialysis patients. The "khichav" may also extend to the legs (patients often describe it as abdominal or generalized early on). Concurrent differentials to consider:
| Differential | Features |
|---|
| Restless Legs Syndrome (most likely) | Creeping/stretching/pulling sensation, worse at rest and night, relieved by movement, insomnia |
| Uremic peripheral neuropathy | Burning, tingling, numbness in extremities |
| Gastroparesis/uremic dysmotility | Abdominal bloating, stretching, early satiety, nausea |
| Muscle cramps (uremic) | Acute painful cramps, often post-dialysis |
| Constipation | Abdominal distension, reduced bowel movements (very common on phosphate binders + fluid restriction) |
CAUSES (Pathophysiology)
1. Restless Legs Syndrome in MHD:
- Reduced dopaminergic modulation of intracortical excitability with reduced supraspinal inhibition and increased spinal cord excitability
- Iron deficiency (common in dialysis) - iron is a cofactor for tyrosine hydroxylase (rate-limiting step in dopamine synthesis); disturbed iron storage in basal ganglia reduces dopamine receptor binding
- Uremic toxin accumulation
- Anemia (stimulates RLS)
- CKD-mineral bone disorder (abnormal Ca/PO4 metabolism)
- RLS affects 12-55% of hemodialysis patients (global meta-analysis, PMID 38376019)
2. Uremic Gastroparesis (if abdominal):
- Autonomic neuropathy (particularly vagal) from diabetes or uremia
- Reduced gastric motilin receptor activation
- Leads to gastroparesis, early satiety, bloating/stretching feeling
3. Uremic Neuropathy:
- Axonal polyneuropathy due to uremic toxins
- Length-dependent, affects longest fibers first
INVESTIGATIONS
First-line:
| Test | Rationale |
|---|
| CBC | Anemia assessment (Hb, MCV) |
| Serum ferritin + transferrin saturation | Iron deficiency - key trigger for RLS |
| Serum iron / TIBC | Iron stores |
| Serum Ca, PO4, Mg | Electrolyte imbalance triggers cramps and RLS |
| Serum PTH | CKD-MBD assessment |
| Urea, Creatinine, eGFR | Adequacy of dialysis (Kt/V) |
| KFT (pre and post dialysis) | Dialysis adequacy |
| RBS/HbA1c | Diabetic gastroparesis / neuropathy |
| Serum albumin | Nutritional status |
| Serum electrolytes (Na, K) | Electrolyte imbalances |
Second-line (if indicated):
| Test | Rationale |
|---|
| Polysomnography | Confirm RLS vs. periodic limb movement disorder vs. obstructive sleep apnea |
| Nerve conduction velocity (NCV) | Peripheral neuropathy assessment |
| Upper GI endoscopy / USG abdomen | If gastroparesis/GI pathology suspected |
| X-ray abdomen | Constipation, bowel gas pattern |
| Vitamin B12, folate | Nutritional neuropathy |
PRESCRIPTION / MANAGEMENT
A. For RLS / Khichav sensation + Insomnia:
Step 1 - Correct reversible causes first:
- IV Iron sucrose (if ferritin < 200 or transferrin sat < 20%) - standard in MHD
- Optimize Hb with EPO/darbepoetin if Hb < 10 g/dL
- Correct Ca/PO4/Mg imbalances
- Optimize dialysis adequacy (target Kt/V ≥ 1.4)
Step 2 - Pharmacological (prescribe one of):
| Drug | Dose | Notes |
|---|
| Tab. Pramipexole 0.125-0.25 mg | 1-2 hours before bedtime | First-line dopamine agonist; start low, titrate |
| Tab. Ropinirole 0.25 mg | 1-2 hours before bedtime | Alternative dopamine agonist |
| Tab. Gabapentin 100 mg | At night or post-dialysis session | Use cautiously in MHD - dose after each HD session; reduces RLS + insomnia + pruritus |
| Levodopa/Carbidopa 100/25 mg | At bedtime | If dopamine agonists not tolerated |
| Tab. Clonazepam 0.5 mg | At bedtime | For sleep + RLS; use cautiously in elderly |
Preferred in MHD: Gabapentin 100-200 mg post-hemodialysis (dialyzable, so give after session) is often practical and helps RLS + pruritus + insomnia simultaneously.
Note: Avoid pregabalin/gabapentin accumulation between sessions - dose after HD only.
B. For Gastroparesis/Abdominal Dysmotility (if contributing):
- Tab. Metoclopramide 10 mg before meals / at bedtime (prokinetic)
- Tab. Domperidone 10-20 mg TDS before meals
- Erythromycin 125-250 mg QID (motilin agonist) - short course only
C. For Constipation (if applicable):
- Lactulose 15-30 mL BD (osmotic laxative - safe in CKD)
- Bisacodyl 5-10 mg at bedtime
- Increase dietary fiber within fluid restrictions
D. For Sleep (adjunct):
- Melatonin 3-5 mg at bedtime (safe in CKD, minimal renal excretion)
- Treat underlying RLS first - sleep usually improves
Sample Prescription (Most Likely - RLS-dominant):
Rx:
1. Tab. Gabapentin 100 mg - 1 tab after hemodialysis session, at night
(Give POST-dialysis session only; not between sessions)
2. Tab. Pramipexole 0.125 mg - 1 tab at 9 PM (1-2 hrs before sleep)
Review after 2 weeks; may increase to 0.25 mg if needed
3. Inj. Iron Sucrose 200 mg IV - during next 3 HD sessions
(after checking ferritin and transferrin saturation)
4. Melatonin 3 mg - at bedtime
5. Tab. Domperidone 10 mg TDS before meals
(if abdominal bloating/gastroparesis component)
Advice: Avoid caffeine in evening, gentle leg stretching before sleep
Follow up: After next HD session
Key Points to Remember in MHD Patients:
- Iron deficiency must be corrected before or alongside drug therapy for RLS
- Gabapentin must be dosed only after dialysis (it is removed by HD, so inter-dialytic accumulation is avoided, but post-HD dosing provides next-session relief)
- Augmentation (worsening/earlier onset with dopaminergic drugs long-term) is a risk - switch to gabapentin/pregabalin if it occurs
- Optimize dialysis adequacy - better clearance reduces uremic RLS
- RLS often partially improves after renal transplantation
Sources: Comprehensive Clinical Nephrology 7th Ed. (Sleep Disorders, p.1201) | Adams & Victor's Principles of Neurology 12th Ed. (RLS Treatment) | Brenner & Rector's The Kidney (Dialysis Complications) | PMID 38376019 (meta-analysis: RLS prevalence 12-55% in HD) |
BC Renal RLS Guidelines